NASDAQ:RNLX Renalytix (RNLX) Stock Price, News & Analysis → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free RNLX Stock Alerts $0.45 0.00 (0.00%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$0.45▼$0.4650-Day Range$0.36▼$0.9352-Week Range$0.24▼$4.04Volume77,391 shsAverage Volume257,171 shsMarket Capitalization$34.81 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Renalytix alerts: Email Address Renalytix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,008.6% Upside$5.00 Price TargetShort InterestHealthy0.58% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.69 out of 5 starsComputer And Technology Sector453rd out of 575 stocksMedical Laboratories Industry14th out of 19 stocks 3.5 Analyst's Opinion Consensus RatingRenalytix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageRenalytix has received no research coverage in the past 90 days.Read more about Renalytix's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.58% of the outstanding shares of Renalytix have been sold short.Short Interest Ratio / Days to CoverRenalytix has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Renalytix has recently decreased by 28.82%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRenalytix does not currently pay a dividend.Dividend GrowthRenalytix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RNLX. Previous Next 1.1 News and Social Media Coverage Search Interest3 people have searched for RNLX on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Renalytix to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Renalytix insiders have not sold or bought any company stock.Percentage Held by Insiders18.30% of the stock of Renalytix is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.92% of the stock of Renalytix is held by institutions.Read more about Renalytix's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Renalytix is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Renalytix is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRenalytix has a P/B Ratio of 3.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Renalytix's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. About Renalytix Stock (NASDAQ:RNLX)Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.Read More RNLX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RNLX Stock News HeadlinesMay 15, 2024 | investorplace.comRNLX Stock Earnings: Renalytix Misses EPS, Misses Revenue for Q3 2024May 15, 2024 | msn.comRenalytix AI GAAP EPS of -$0.08 beats by $0.01, revenue of $0.54M misses by $0.56MMay 15, 2024 | globenewswire.comRenalytix Reports Financial Results for Third Quarter of Fiscal Year 2024May 15, 2024 | markets.businessinsider.comRenalytix AI is about to announce its earnings — here's what Wall Street expectsMay 14, 2024 | markets.businessinsider.comRenalytix AI earnings: here's what Wall Street expectsMay 9, 2024 | finance.yahoo.comRenalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15May 9, 2024 | globenewswire.comRenalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15April 28, 2024 | finance.yahoo.comRenalytix Plc (RNLX) Stock Price, News, Quote & History - Yahoo FinanceApril 17, 2024 | msn.comRenalytix files to sell 19.99M ordinary shares for holdersApril 9, 2024 | marketwatch.comRenalytix Sells Stock to Raise Up to $4 MlnApril 8, 2024 | globenewswire.comRenalytix Announces Financing with Expected Size of up to $4 MillionMarch 25, 2024 | investorplace.com3 Ridiculously Enticing Stocks to Buy for Under a BuckMarch 14, 2024 | stockhouse.comKidneyIntelX(TM) included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)March 14, 2024 | globenewswire.comKidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)March 12, 2024 | msn.comGoogle restricts election queries by AI model Gemini - reportMarch 12, 2024 | msn.comNew Zealand air-safety authorities to seize flight recorders for Latam 787March 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for Renalytix AI Amidst Potential Acquisition and Strong Market ProspectsMarch 4, 2024 | msn.comWhy Is AI-Powered Diagnostic Firm Renalytix Stock Soaring On Monday?March 4, 2024 | msn.comRenalytix approached by potential buyer, stock rallies 28%February 29, 2024 | msn.comWhy Is Kidney-Disease Diagnostic Focused Renalytix Stock Trading Higher Today?February 24, 2024 | msn.comRenalytix Plc - Depositary Receipt () (RNLX) Price Target Increased by 21.81% to 5.97February 15, 2024 | finance.yahoo.comRenalytix Reports Financial Results for Second Quarter of Fiscal Year 2024February 15, 2024 | globenewswire.comRenalytix Reports Financial Results for Second Quarter of Fiscal Year 2024February 13, 2024 | msn.comU.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.33%February 12, 2024 | msn.comRenalytix surges after Medicare draft decision on lead productSee More Headlines Receive RNLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/09/2024Fiscal Year End6/30/2024Next Earnings (Estimated)9/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:RNLX CUSIPN/A CIK1811115 Webwww.renalytixai.com Phone44-20-3139-2910FaxN/AEmployees102Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,008.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45,610,000.00 Net Margins-1,687.80% Pretax Margin-1,687.44% Return on Equity-1,008.88% Return on Assets-205.46% Debt Debt-to-Equity RatioN/A Current Ratio0.42 Quick Ratio0.42 Sales & Book Value Annual Sales$3.40 million Price / Sales10.24 Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book3.01Miscellaneous Outstanding Shares77,180,000Free Float63,059,000Market Cap$34.81 million OptionableOptionable Beta2.88 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. James R. McCullough M.B.A. (Age 56)Chief Executive Officer Comp: $1.04MMr. Oliver James Sterling IIIChief Financial OfficerMr. Fergus Fleming (Age 56)Chief Technology Officer Mr. Salim Gulamabbas Hamir F.C.A.Company SecretaryKey CompetitorsBurning Rock BiotechNASDAQ:BNRPersonalisNASDAQ:PSNLEnzo BiochemNYSE:ENZExagenNASDAQ:XGNPsychemedicsNASDAQ:PMDView All CompetitorsInstitutional OwnershipPinnacle Associates Ltd.Sold 150,529 shares on 4/26/2024Ownership: 1.127%View All Institutional Transactions RNLX Stock Analysis - Frequently Asked Questions Should I buy or sell Renalytix stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Renalytix in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" RNLX shares. View RNLX analyst ratings or view top-rated stocks. What is Renalytix's stock price target for 2024? 1 brokerages have issued 12-month price targets for Renalytix's shares. Their RNLX share price targets range from $5.00 to $5.00. On average, they anticipate the company's share price to reach $5.00 in the next year. This suggests a possible upside of 1,008.6% from the stock's current price. View analysts price targets for RNLX or view top-rated stocks among Wall Street analysts. How have RNLX shares performed in 2024? Renalytix's stock was trading at $0.39 at the start of the year. Since then, RNLX stock has increased by 15.6% and is now trading at $0.4510. View the best growth stocks for 2024 here. Are investors shorting Renalytix? Renalytix saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 446,600 shares, a decline of 28.8% from the April 30th total of 627,400 shares. Based on an average daily volume of 810,900 shares, the short-interest ratio is presently 0.6 days. View Renalytix's Short Interest. When is Renalytix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, September 26th 2024. View our RNLX earnings forecast. How were Renalytix's earnings last quarter? Renalytix Plc (NASDAQ:RNLX) announced its earnings results on Wednesday, May, 15th. The company reported ($0.08) EPS for the quarter. The business had revenue of $0.54 million for the quarter. Renalytix had a negative trailing twelve-month return on equity of 1,008.88% and a negative net margin of 1,687.80%. What other stocks do shareholders of Renalytix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Renalytix investors own include Trevena (TRVN), Advanced Micro Devices (AMD), ChromaDex (CDXC), Chimerix (CMRX), CTI BioPharma (CTIC), DRDGOLD (DRD), Forte Biosciences (FBRX). When did Renalytix IPO? Renalytix (RNLX) raised $156 million in an initial public offering on Friday, July 17th 2020. The company issued 11,000,000 shares at $14.22 per share. J.P. Morgan and Stifel served as the underwriters for the IPO. Who are Renalytix's major shareholders? Renalytix's stock is owned by many different retail and institutional investors. Top institutional shareholders include Pinnacle Associates Ltd. (1.13%). How do I buy shares of Renalytix? Shares of RNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RNLX) was last updated on 6/9/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renalytix Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Renalytix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
